Related Experiment Video

Updated: May 9, 2026

Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model
13:41

Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model

Published on: January 13, 2023

Rhabdoid tumors: clinical approaches and molecular targets for innovative therapy

Kornelius Kerl1, Till Holsten, Michael C Frühwald

  • 1Institute of Molecular Tumor Biology (IMTB), Westfalian Wilhelms University (WWU), M¨unster, Germany, Robert-Koch Strasse 43, 48149M¨unster, Germany.

Pediatric Hematology and Oncology
|July 16, 2013
PubMed

Insights

Rhabdoid tumors, often driven by SMARCB1 mutations, are aggressive childhood cancers. While treatments have improved, many patients relapse, highlighting the need for novel targeted therapies.

Area of Science:

  • Pediatric Oncology
  • Molecular Genetics
  • Cancer Biology

Background:

  • Rhabdoid tumors are rare, aggressive pediatric cancers.
  • Most cases involve biallelic SMARCB1/INI1/hSNF5 mutations; rare cases affect other SWI/SNF members like BRG1.
  • Despite recent treatment advances, over 50% of patients relapse, necessitating improved therapeutic strategies.

Purpose of the Study:

  • To review current and past clinical management of rhabdoid tumors.
  • To explore the genetic underpinnings of rhabdoid tumor development.
  • To identify rationales for targeted therapies in future clinical trials.

Main Methods:

  • Literature review of clinical trials and treatment recommendations.
  • Analysis of genetic mutations in SWI/SNF core members.
  • Summary of therapeutic approaches and future directions.

Main Results:

  • Rhabdoid tumors predominantly harbor SMARCB1 mutations.
  • Clinical trials have led to improved, yet insufficient, patient prognoses.
  • Targeted therapy rationales are emerging for rhabdoid tumors.

Conclusions:

  • Rhabdoid tumors remain a significant challenge in pediatric oncology.
  • Understanding SWI/SNF pathway mutations is crucial for therapeutic development.
  • Future research should focus on targeted therapies to overcome relapse and improve survival rates.

More Related Videos

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas09:21

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas

Published on: September 13, 2019

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...